Jakafi
Payments companies reported to CMS as associated with Jakafi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jakafi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jakafi
These are the largest totals companies reported as associated with Jakafi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ahmed Galal | Morristown, NJ | Hematology (Internal Medicine) | $319,016.46 |
| Shahram Mori | Orlando, FL | Hematology & Oncology | $291,374.25 |
| Hana Safah | Baton Rouge, LA | Hematology & Oncology | $226,170.61 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $205,071.33 |
| Harry Erba | Ann Arbor, MI | Medical Oncology | $192,664.03 |
| Jason Salganick | Phoenix, AZ | Medical Oncology | $191,764.94 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $188,343.49 |
| Michael Scola | Morristown, NJ | Hematology & Oncology | $160,975.73 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $154,084.33 |
| Mohamad Khair Khasawneh | Maywood, IL | Hematology & Oncology | $111,377.57 |
Prescribed Jakafi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.